001     178883
005     20240229143558.0
024 7 _ |a 10.1016/j.radonc.2022.02.009
|2 doi
024 7 _ |a pmid:35182686
|2 pmid
024 7 _ |a 0167-8140
|2 ISSN
024 7 _ |a 1879-0887
|2 ISSN
024 7 _ |a altmetric:123162135
|2 altmetric
037 _ _ |a DKFZ-2022-00318
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Löck, Steffen
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - hypothesis generation on a multicentre cohort of the DKTK-ROG.
260 _ _ |a Amsterdam [u.a.]
|c 2022
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1651579637_6244
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2022 Apr;169:8-14
520 _ _ |a To develop prognostic biomarker signatures for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated by primary radiochemotherapy (RCTx) based on previously published molecular analyses of the retrospective biomarker study of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG).In previous studies on the retrospective DKTK-ROG HNSCC cohort treated with primary RCTx, the following clinical parameters and biomarkers were evaluated and found to be significantly associated with loco-regional tumour control (LRC) or overall survival (OS): tumour volume, p16 status, expression of cancer stem cell markers CD44 and SLC3A2, expressions of hypoxia-associated gene signatures, tumour mutational burden (TMB), single nucleotide polymorphisms (SNPs) in the ERCC2 gene (rs1799793, rs13181) and ERCC5 gene (rs17655) as well as the expression of CXCR4, SDF-1 and CD8. These biomarkers were combined in multivariable modelling using Cox-regression with backward variable selection.A baseline signature containing the widely accepted parameters tumour volume, p16 status, cancer stem cell marker expression (CD44) and hypoxia-associated gene expression has been defined, representing the main hypothesis of the study. Furthermore, the baseline signature was extended by additional prognostic biomarkers and a data-driven signature without any pre-hypothesis was generated for both endpoints. In these signatures, the SNPs rs1799793 and rs17655 as well as CXCR4, SDF-1 and SLC3A2 expression were additionally included. The signatures showed significant patient stratifications for LRC and OS.Three biomarker signatures were defined for patients with locally advanced HNSCC treated with primary RCTx for the endpoints LRC and OS. These signatures will be validated in the prospective HNprädBio study of the DKTK-ROG that recently completed recruitment, before potential application in an interventional trial.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Biomarkers
|2 Other
650 _ 7 |a HNSCC
|2 Other
650 _ 7 |a Primary radiochemotherapy
|2 Other
650 _ 7 |a Signature
|2 Other
650 _ 7 |a Validation
|2 Other
700 1 _ |a Linge, Annett
|0 P:(DE-He78)81b719227985a27b1b77ed6766094319
|b 1
700 1 _ |a Lohaus, Fabian
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Ebert, Nadja
|0 P:(DE-He78)8bff76ab3cfe753721744ece2dfa32e5
|b 3
|u dkfz
700 1 _ |a Gudziol, Volker
|b 4
700 1 _ |a Nowak, Alexander
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Tinhofer, Ingeborg
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Kalinauskaite, Goda
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Guberina, Maja
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Stuschke, Martin
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Balermpas, Panagiotis
|0 P:(DE-HGF)0
|b 10
700 1 _ |a von der Grün, Jens
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Grosu, Anca-Ligia
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Debus, Jürgen
|0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
|b 13
|u dkfz
700 1 _ |a Ganswindt, Ute
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Belka, Claus
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Peeken, Jan C
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Combs, Stephanie E
|0 P:(DE-HGF)0
|b 17
700 1 _ |a De-Colle, Chiara
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Zips, Daniel
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Baretton, Gustavo B
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Krause, Mechthild
|0 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9
|b 21
|u dkfz
700 1 _ |a Baumann, Michael
|0 P:(DE-He78)933f7d725ac87378f459623783585a1f
|b 22
|u dkfz
700 1 _ |a DKTK-ROG
|0 P:(DE-HGF)0
|b 23
773 _ _ |a 10.1016/j.radonc.2022.02.009
|g p. S0167814022000949
|0 PERI:(DE-600)1500707-8
|p 8-14
|t Radiotherapy and oncology
|v 169
|y 2022
|x 0167-8140
909 C O |p VDB
|o oai:inrepo02.dkfz.de:178883
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)81b719227985a27b1b77ed6766094319
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)8bff76ab3cfe753721744ece2dfa32e5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)933f7d725ac87378f459623783585a1f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 23
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-31
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-31
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-29
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-29
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b RADIOTHER ONCOL : 2021
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-29
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-29
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b RADIOTHER ONCOL : 2021
|d 2022-11-29
920 1 _ |0 I:(DE-He78)DD01-20160331
|k DD01
|l DKTK DD zentral
|x 0
920 1 _ |0 I:(DE-He78)BE01-20160331
|k BE01
|l DKTK BE zentral
|x 1
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK ED ES zentral
|x 2
920 1 _ |0 I:(DE-He78)FM01-20160331
|k FM01
|l DKTK FM zentral
|x 3
920 1 _ |0 I:(DE-He78)FR01-20160331
|k FR01
|l DKTK FR zentral
|x 4
920 1 _ |0 I:(DE-He78)E050-20160331
|k E050
|l E050 KKE Strahlentherapie
|x 5
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 6
920 1 _ |0 I:(DE-He78)MU01-20160331
|k MU01
|l DKTK MU LMU zentral
|x 7
920 1 _ |0 I:(DE-He78)TU01-20160331
|k TU01
|l DKTK TU zentral
|x 8
920 1 _ |0 I:(DE-He78)E220-20160331
|k E220
|l E220 Radioonkologie/Radiobiologie
|x 9
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)DD01-20160331
980 _ _ |a I:(DE-He78)BE01-20160331
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a I:(DE-He78)FM01-20160331
980 _ _ |a I:(DE-He78)FR01-20160331
980 _ _ |a I:(DE-He78)E050-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)MU01-20160331
980 _ _ |a I:(DE-He78)TU01-20160331
980 _ _ |a I:(DE-He78)E220-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21